【摘要】：目前我國(guó)的中小型制藥企業(yè)占制藥企業(yè)總數(shù)的絕大多數(shù)，藥品研發(fā)也多以仿制藥品種為主，缺乏系統(tǒng)有效的規(guī)劃與戰(zhàn)略，中小企業(yè)如何通過(guò)藥品研發(fā)戰(zhàn)略的制定與實(shí)施，實(shí)現(xiàn)品種的創(chuàng)新獲取競(jìng)爭(zhēng)優(yōu)勢(shì)，國(guó)內(nèi)目前對(duì)此研究較少，本文通過(guò)對(duì)EY制藥的研發(fā)狀況的分析與研究，，提出了EY制藥的藥品研發(fā)戰(zhàn)略與實(shí)施的保障措施。 論文研究中理論與實(shí)踐相結(jié)合，首先對(duì)國(guó)內(nèi)制藥行業(yè)現(xiàn)狀與企業(yè)藥品研發(fā)戰(zhàn)略研究情況進(jìn)行回顧，其次運(yùn)用企業(yè)競(jìng)爭(zhēng)力理論、戰(zhàn)略管理理論、產(chǎn)品生命周期理論，分析了EY制藥藥品研發(fā)的內(nèi)部?jī)?yōu)勢(shì)和劣勢(shì)及面臨外部的競(jìng)爭(zhēng)環(huán)境，按照利用內(nèi)部?jī)?yōu)勢(shì)資源和外部機(jī)會(huì)，回避內(nèi)部劣勢(shì)和外部威脅的思路，提出了EY制藥的藥品研發(fā)戰(zhàn)略：在新產(chǎn)品選擇上，重點(diǎn)先開(kāi)發(fā)市場(chǎng)前景好的仿制藥和對(duì)已有品種的二次開(kāi)發(fā)，再開(kāi)發(fā)相對(duì)容易成功的“me一too”藥物，最終實(shí)現(xiàn)完全創(chuàng)新品種的研發(fā)；在藥品研發(fā)模式上，可以根據(jù)不同情形選擇聯(lián)合研發(fā)與自主研發(fā)，需特別重視與CRO公司合作；三是在研發(fā)投入機(jī)制上，可以實(shí)行多渠道融資形式，獲取研發(fā)資金。同時(shí)提出了EY制藥藥品研發(fā)的戰(zhàn)略重點(diǎn)，為戰(zhàn)略實(shí)施提供原則性指導(dǎo)，最后制定出詳細(xì)的藥品研發(fā)戰(zhàn)略實(shí)施步驟，以及EY制藥藥品研發(fā)戰(zhàn)略實(shí)施的配套保障措施。 藥品研發(fā)戰(zhàn)略是制藥企業(yè)發(fā)展戰(zhàn)略的重要組成部分，論文嘗試幫助EY制藥制定藥品研發(fā)戰(zhàn)略，并制定措施保障戰(zhàn)略實(shí)施，給企業(yè)在研發(fā)方向選擇上給予明確指導(dǎo)，從而實(shí)現(xiàn)企業(yè)的發(fā)展戰(zhàn)略規(guī)劃，也為國(guó)內(nèi)其他中小制藥企業(yè)戰(zhàn)略制定提供參考，為促進(jìn)我國(guó)醫(yī)藥產(chǎn)業(yè)的做大做強(qiáng)盡一份努力。
[Abstract]:At present, the small and medium-sized pharmaceutical enterprises in China account for the vast majority of the total number of pharmaceutical enterprises, and the majority of drug research and development is mainly based on generic drugs. There is a lack of systematic and effective planning and strategy. How to formulate and implement the drug research and development strategy by SMEs? At present, there is little research on this issue in China. Through the analysis and research on the research and development status of EY pharmaceutical, this paper puts forward the R & D strategy of EY pharmaceutical and the guarantee measures for its implementation. Firstly, the current situation of domestic pharmaceutical industry and the research situation of drug research and development strategy are reviewed. Secondly, the theory of enterprise competitiveness, the theory of strategic management, the theory of product life cycle, and the theory of product life cycle are used. The internal strengths and weaknesses of EY pharmaceutical research and development and the external competitive environment are analyzed. According to the idea of using internal advantage resources and external opportunities to avoid internal weaknesses and external threats, The strategy of drug research and development for EY Pharmaceuticals is put forward: in the selection of new products, the emphasis should be placed on the development of generic drugs with good market prospects and the secondary development of existing products, and then the relatively successful "me-too" drugs, which are relatively easy to be successfully developed. Finally realize the research and development of completely innovative varieties; In the mode of drug research and development, joint R & D and independent R & D can be selected according to different situations, and special attention should be paid to cooperating with CRO Company. Thirdly, in R & D input mechanism, multi-channel financing can be carried out to obtain R & D funds. At the same time, the strategic emphasis of EY pharmaceutical drug research and development is put forward, which provides the principle guidance for the implementation of the strategy. Finally, the detailed implementation steps of the drug R & D strategy and the supporting safeguard measures for the implementation of the EY pharmaceutical drug R & D strategy are worked out. Drug research and development strategy is an important part of the development strategy of pharmaceutical enterprises. This paper attempts to help EY pharmaceutical to formulate drug research and development strategy, and to formulate measures to ensure the implementation of the strategy, so as to give clear guidance to enterprises in the choice of R & D direction. In order to realize the strategic planning of the development of enterprises, it also provides reference for other small and medium-sized pharmaceutical enterprises in China, and makes a great effort to promote the growth and strength of the pharmaceutical industry in China.
【學(xué)位授予單位】：蘇州大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2014
【分類號(hào)】：F426.72;F273.2

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 徐晶晶;;我國(guó)醫(yī)藥企業(yè)在藥品研發(fā)階段社會(huì)責(zé)任缺失的原因及改進(jìn)方法[J];才智;2010年11期

2 楊成志;;中國(guó)研發(fā)路漫漫[J];當(dāng)代醫(yī)學(xué);2006年04期

3 唐玲,邱家學(xué);談我國(guó)制藥企業(yè)的藥品研發(fā)問(wèn)題[J];國(guó)際醫(yī)藥衛(wèi)生導(dǎo)報(bào);2005年13期

4 孫茂龍;徐雪昱;任繼勤;;我國(guó)醫(yī)藥制造業(yè)的現(xiàn)狀及發(fā)展對(duì)策[J];化工管理;2012年11期

5 張軍;;產(chǎn)品生命周期理論及其適用性分析[J];華北電力大學(xué)學(xué)報(bào)(社會(huì)科學(xué)版);2008年01期

6 劉蘭茹;方志偉;蘭恭贊;;我國(guó)醫(yī)藥知識(shí)產(chǎn)權(quán)的現(xiàn)狀及策略研究[J];哈爾濱商業(yè)大學(xué)學(xué)報(bào)(社會(huì)科學(xué)版);2006年04期

7 王繼東;李潮濱;;淺析我國(guó)藥品營(yíng)銷現(xiàn)狀及發(fā)展[J];黑龍江科技信息;2010年19期

8 程志新;李海娟;胡春;;Me-too策略在新藥研究開(kāi)發(fā)中的應(yīng)用[J];精細(xì)化工中間體;2011年03期

9 徐全軍;企業(yè)競(jìng)爭(zhēng)力理論基礎(chǔ)述評(píng)[J];經(jīng)濟(jì)體制改革;2004年05期

10 周毅;鄧明然;王華;;有限研發(fā)投入的高科技企業(yè)研發(fā)戰(zhàn)略管理[J];科技進(jìn)步與對(duì)策;2003年13期

本文編號(hào)：2438777